DOPF

DOPF
Clinical data
Other names	DOPF; 2,5-Dimethoxy-4-(3-fluoropropyl)amphetamine
Identifiers
	IUPAC name 2-[4-(3-fluoropropyl)-2,5-dimethoxyphenyl]ethanamine;
PubChem CID	163192484;
ChemSpider	129558527;
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).;
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C14H22FNO2
Molar mass	255.333 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1cc(CCCF)c(cc1CC(C)N)OC;
	InChI InChI=1S/C14H22FNO2/c1-10(16)7-12-9-13(17-2)11(5-4-6-15)8-14(12)18-3/h8-10H,4-7,16H2,1-3H3; Key:UIHSFMYQJAKMHD-UHFFFAOYSA-N;

2,5-Dimethoxy-4-(3-fluoropropyl)amphetamine (DOPF) is a designer drug from the amphetamine and DOx families. It was first synthesised by Alexander Shulgin and David Nichols in 1989 but was never published at the time, and was finally disclosed in Daniel Trachsel's review of the field in 2013. It has a binding affinity (K_i) of 9 nM at the serotonin receptor 5-HT_2A but is not known to have been tested in humans.^[1]

References

^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.